{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:00:03Z","timestamp":1775700003408,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eimce.2026.503103","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:53:57Z","timestamp":1775681637000},"page":"503103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro activity of eravacycline against anaerobic bacteria isolated from clinically significant samples"],"prefix":"10.1016","volume":"44","author":[{"given":"Fernando","family":"Cobo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rodr\u00edguez-Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Sampedro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Reguera-M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Navarro-Mar\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2026.503103_bib0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/jm201465w","article-title":"Fluorocyclines: 1.7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent","volume":"55","author":"Xiao","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.eimce.2026.503103_bib0070","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2026.503103_bib0075","first-page":"224","article-title":"Assessing the efficacy and safety of eravacycline versus ertapenem in complicated intraabdominal infections in the \u201cInvestigating Gram-negative infections treated with eravacycline (IGNITE-1)\u201d trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2016","journal-title":"J Am Med Assoc Surg"},{"key":"10.1016\/j.eimce.2026.503103_bib0080","first-page":"3607125","article-title":"Multidrug \u2013 resistant Bacteroides fragilis bacteremia in a US resident: an emerging challenge","volume":"2016","author":"Merchan","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.eimce.2026.503103_bib0085","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/jmm.0.043927-0","article-title":"The value of MALDI-TOF MS for the identification of clinically relevant anaerobic bacteria in routine laboratories","volume":"61","author":"Nagy","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.eimce.2026.503103_bib0090","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/nar\/gks808","article-title":"Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies","volume":"41","author":"Klindworth","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.eimce.2026.503103_bib0095","series-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 15.0","article-title":"European Committee on antimicrobial susceptibility testing","year":"2025"},{"key":"10.1016\/j.eimce.2026.503103_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10096-023-04708-4","article-title":"Fifty years devoted to anaerobes: historical, lessons, and highlights","volume":"43","author":"Dubreuil","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimce.2026.503103_bib0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anaerobe.2018.06.016","article-title":"In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species","volume":"52","author":"Goldstein","year":"2018","journal-title":"Anaerobe"},{"key":"10.1016\/j.eimce.2026.503103_bib0110","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2026.503103_bib0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/antibiotics12010063","article-title":"Antimicrobial susceptibility profile of rare anaerobic bacteria","volume":"12","author":"Wolf","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.eimce.2026.503103_bib0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: a clinical microbiological study","volume":"37","author":"Tsai","year":"2024","journal-title":"J Global Antimicrob Resist"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X26000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:29:33Z","timestamp":1775698173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X26000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2529993X26000560"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503103","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of eravacycline against anaerobic bacteria isolated from clinically significant samples","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2026.503103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"503103"}}